One of the most interesting aspects concerning the role of PARP-1 in tumor immunology was a report demonstrating upregulation of the immunosuppressive cancer cell ligand PD-L1 in breast cancer cells treated with the PARP inhibitors, olaparib, talazoparib, and rucaparib [151]. The gene discussed is PARP1; the disease is cancer.